TG Therapeutics, Inc. (TGTX)

Market Cap	4.47B
Revenue (ttm)	264.79M
Net Income (ttm)	-14.36M
Shares Out	143.52M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	43.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,176,723
Open	30.45
Previous Close	30.32
Day's Range	29.96 - 31.71
52-Week Range	12.26 - 36.50
Beta	2.19
Analysts	Strong Buy
Price Target	37.67 (+20.93%)
Earnings Date	Nov 4, 2024

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 14, 1995
• Employees: 264
• Stock Exchange: NASDAQ
• Ticker Symbol: TGTX
• Website: https://www.tgtherapeutics.com

Analyst Forecast

According to 6 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is $37.67, which is an increase of 20.93% from the latest price.

Price Target

$37.67

(20.93% upside)

Analyst Consensus: Strong Buy